These findings agree well with our observations on the roles of N192 and N200 in regulating PD-L1 functions and STAT3/STAT1 activities in breast cancer cells, and offer new therapeutic opportunities that rely on targeted inhibition of the most active form of PD-L1, the one which is fully N-linked glycosylated. The gene discussed is STAT3; the disease is breast carcinoma.